Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Chief Business Officer | August 12, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edgewise Therapeutics, Inc.
Report date August 12, 2026 · Filed August 17, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2036-08-12 | Direct | 100,000 |
Reported balance
After 2026-08-12 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 100,000 · Balance 100,000 F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 10 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-08-12 F9 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 9 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-08-12 F8 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 8 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires 2035-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · derivative · entry 7 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,563 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,475 | $43.70 | $108,153.54 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 6 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,826 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F5 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.29 to $44.14, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 150 | $44.44 | $6,666.50 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 5 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,301 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.415 to $44.50, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 304 | $44.50 | $13,528.55 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 4 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,451 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.47 to $44.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,171 | $43.79 | $95,075.47 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,755 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.30 to $44.145, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:53 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001853109-26-000001 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:39 UTC Amendment | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001853109-26-000002 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $13.39 | $0.00 |
DisclosureSEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 5 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2035-08-12 F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 4 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2035-08-12 F4 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,781 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005798 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,344 Underlying: Common Stock · 5,781 shares Expires 2034-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 2,491 | $13.39 | $33,360.47 |
DisclosureSEC source: 0001562180-25-005798 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,645 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2025 Filed Aug 14, 2025 23:43 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,781 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005798 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,136 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,691 | $16.45 | $27,824.05 |
DisclosureSEC source: 0001562180-25-003656 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,355 F1 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $16.07 to $16.84, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,209 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003656 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,209 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2025 Filed May 8, 2025 01:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,209 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-003656 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:37 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-25-001024 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,929 Underlying: Common Stock · 10,000 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:37 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 10,000 | $30.03 | $300,300.00 |
DisclosureSEC source: 0001562180-25-001024 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,837 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 30, 2024. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.13, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:37 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 10,000 | $1.93 | $19,300.00 |
DisclosureSEC source: 0001562180-25-001024 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,716 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,068 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-006943 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,949 Underlying: Common Stock · 4,763 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 42,068 | $29.03 | $1,221,133.08 |
DisclosureSEC source: 0001562180-24-006943 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,121 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.28, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 25, 2024 00:24 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 42,068 | $1.93 | $81,191.24 |
DisclosureSEC source: 0001562180-24-006943 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,189 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,699 shares purchased on May 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 23,125 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-006259 · primarydocument.xml · derivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,125 Underlying: Common Stock · 23,125 shares Expires 2034-08-12 F2 · derivative.exercise_date: Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2024. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 138,750 | $0.00 Strike: $17.05 | $0.00 |
DisclosureSEC source: 0001562180-24-006259 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,750 Underlying: Common Stock · 138,750 shares Expires 2034-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on August 12, 2024, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:29 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,718 | $18.91 | $32,487.38 |
DisclosureSEC source: 0001562180-24-003828 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,422 F2 · kind: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:29 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003828 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,209 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:29 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-003828 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,140 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2024 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,800 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · derivative · entry 9 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 145,017 Underlying: Common Stock · 4,800 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,800 | $20.04 | $96,209.28 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 6 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,020 F4 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.135, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 09, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,800 | $1.93 | $9,264.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 5 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · derivative · entry 8 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,817 Underlying: Common Stock · 4,600 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 4,600 | $20.01 | $92,048.76 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 4 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,020 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.04, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 4,600 | $1.93 | $8,878.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionStock Option (Right to Buy) · Derivative | 600 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · derivative · entry 7 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,417 Underlying: Common Stock · 600 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on January 3, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 600 | $20.00 | $12,000.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,020 Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 22:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 600 | $1.93 | $1,158.00 |
DisclosureSEC source: 0001562180-24-001226 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,620 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on March 30, 2023. F2 · balance_after: Includes 850 shares purchased on November 15, 2022, 1,304 shares purchased on May 15, 2023 and 1,608 shares purchased on November 15, 2023 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 23:13 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001562180-23-006457 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2033-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 02, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | SaleCommon Stock | 1,747 | $8.90 | $15,556.86 |
DisclosureSEC source: 0001562180-23-003923 · primarydocument.xml · nonDerivative · entry 2 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,020 F2 · shares: Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $8.59 to $9.58, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionRestricted Stock Units · Derivative | 5,208 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003923 · primarydocument.xml · derivative · entry 3 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,417 Underlying: Common Stock · 5,208 shares Expires 2032-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| May 01, 2023 Filed May 3, 2023 22:26 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | Exercise / conversionCommon Stock | 5,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-003923 · primarydocument.xml · nonDerivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,470 shares purchased on November 15, 2021, 1,239 shares purchased on May 15, 2022 and 850 shares purchased on November 15, 2022 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| August 08, 2022 Filed Aug 10, 2022 21:42 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001562180-22-006027 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-08-08 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 8, 2022, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| May 01, 2022 Filed May 3, 2022 20:14 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantRestricted Stock Units · Derivative | 15,625 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-003666 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires 2025-05-01 F1 · shares: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. F1 · derivative.exercise_date: RSUs granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023. Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 21:09 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $16.38 | $0.00 |
DisclosureSEC source: 0001562180-21-005460 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2031-08-17 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2021, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.